|
1
|
Riccioni G, Bucciarelli T, Mancini B, Di
Ilio C and D'Orazio N: Antileukotriene drugs: clinical application,
effectiveness and safety. Curr Med Chem. 14:1966–1977. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai MJ, Chang WA, Chuang CH, Wu KL, Cheng
CH, Sheu CC, Hsu YL and Hung JY: Cysteinyl leukotriene pathway and
cancer. Int J Mol Sci. 23:1202021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Magnusson C, Liu J, Ehrnstrom R, Manjer J,
Jirström K, Andersson T and Sjölander A: Cysteinyl leukotriene
receptor expression pattern affects migration of breast cancer
cells and survival of breast cancer patients. Int J Cancer.
129:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsai MJ, Wu PH, Sheu CC, Hsu YL, Chang WA,
Hung JY, Yang CJ, Yang YH, Kuo PL and Huang MS: cysteinyl
leukotriene receptor antagonists decrease cancer risk in asthma
patients. Sci Rep. 6:239792016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jang HY, Kim IW and Oh JM: Cysteinyl
leukotriene receptor antagonists associated with a decreased
incidence of cancer: A retrospective cohort study. Front Oncol.
12:8588552022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maeda-Minami A, Hosokawa M, Ishikura Y,
Onoda A, Kawano Y, Negishi K, Shimada S, Ihara T, Sugamata M,
Takeda K and Mano Y: Relationship between leukotriene receptor
antagonists on cancer development in patients with bronchial
asthma: A retrospective analysis. Anticancer Res. 42:3717–3724.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suknuntha K, Yubolphan R, Krueaprasertkul
K, Srihirun S, Sibmooh N and Vivithanaporn P: Leukotriene receptor
antagonists inhibit mitogenic activity in triple negative breast
cancer cells. Asian Pac J Cancer Prev. 19:833–837. 2018.PubMed/NCBI
|
|
8
|
Piromkraipak P, Sangpairoj K, Tirakotai W,
Chaithirayanon K, Unchern S, Supavilai P, Power C and Vivithanaporn
P: Cysteinyl leukotriene receptor antagonists inhibit migration,
invasion, and expression of MMP-2/9 in human glioblastoma. Cell Mol
Neurobiol. 38:559–573. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsai MJ, Chang WA, Tsai PH, Wu CY, Ho YW,
Yen MC, Lin YS, Kuo PL and Hsu YL: Montelukast induces
apoptosis-inducing factor-mediated cell death of lung cancer cells.
Int J Mol Sci. 18:13532017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piromkraipak P, Parakaw T, Phuagkhaopong
S, Srihirun S, Chongthammakun S, Chaithirayanon K and Vivithanaporn
P: Cysteinyl leukotriene receptor antagonists induce apoptosis and
inhibit proliferation of human glioblastoma cells by downregulating
B-cell lymphoma 2 and inducing cell cycle arrest. Can J Physiol
Pharmacol. 96:798–806. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Phuagkhaopong S, Ospondpant D, Kasemsuk T,
Sibmooh N, Soodvilai S, Power C and Vivithanaporn P:
Cadmium-induced IL-6 and IL-8 expression and release from
astrocytes are mediated by MAPK and NF-κB pathways.
Neurotoxicology. 60:82–91. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aguilar-Quesada R, Munoz-Gamez JA,
Martin-Oliva D, Peralta A, Valenzuela MT, Matínez-Romero R,
Quiles-Pérez R, Menissier-de Murcia J, de Murcia G, Ruiz de
Almodóvar M and Oliver FJ: Interaction between ATM and PARP-1 in
response to DNA damage and sensitization of ATM deficient cells
through PARP inhibition. BMC Mol Biol. 8:292007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Clarke R, Cook KL, Hu R, Facey CO,
Tavassoly I, Schwartz JL, Baumann WT, Tyson JJ, Xuan J, Wang Y, et
al: Endoplasmic reticulum stress, the unfolded protein response,
autophagy, and the integrated regulation of breast cancer cell
fate. Cancer Res. 72:1321–1331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sisinni L, Pietrafesa M, Lepore S,
Maddalena F, Condelli V, Esposito F and Landriscina M: Endoplasmic
reticulum stress and unfolded protein response in breast cancer:
The balance between apoptosis and autophagy and its role in drug
resistance. Int J Mol Sci. 20:8572019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye J, Rawson RB, Komuro R, Chen X, Davé
UP, Prywes R, Brown MS and Goldstein JL: ER stress induces cleavage
of membrane-bound ATF6 by the same proteases that process SREBPs.
Mol Cell. 6:1355–1364. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vermeulen K, Berneman ZN and Van
Bockstaele DR: Cell cycle and apoptosis. Cell Prolif. 36:165–175.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Finkelman BS, Zhang H, Hicks DG and Turner
BM: The Evolution of Ki-67 and Breast Carcinoma: Past observations,
present directions, and future considerations. Cancers (Basel).
15:8082023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu H and Dogan BE: American Joint
Committee on Cancer's Staging System for Breast Cancer, Eighth
Edition: Summary for Clinicians. Eur J Breast Health. 17:234–238.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Paruchuri S, Mezhybovska M, Juhas M and
Sjolander A: Endogenous production of leukotriene D4 mediates
autocrine survival and proliferation via CysLT1 receptor signalling
in intestinal epithelial cells. Oncogene. 25:6660–6665. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stacey DW: Three observations that have
changed our understanding of cyclin D1 and p27 in cell cycle
control. Genes Cancer. 1:1189–1199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hui L, Zheng Y, Yan Y, Bargonetti J and
Foster DA: Mutant p53 in MDA-MB-231 breast cancer cells is
stabilized by elevated phospholipase D activity and contributes to
survival signals generated by phospholipase D. Oncogene.
25:7305–7310. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Georgakilas AG, Martin OA and Bonner WM:
p21: A Two-Faced Genome Guardian. Trends Mol Med. 23:310–319. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Warfel NA and El-Deiry WS: p21WAF1 and
tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Braal CL, Jongbloed EM, Wilting SM,
Mathijssen RHJ, Koolen SLW and Jager A: Inhibiting CDK4/6 in breast
cancer with palbociclib, ribociclib, and abemaciclib: similarities
and differences. Drugs. 81:317–331. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsuse H and Kohno S: Leukotriene
receptor antagonists pranlukast and montelukast for treating
asthma. Expert Opin Pharmacother. 15:353–363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Law SWY, Wong AYS, Anand S, Wong ICK and
Chan EW: Neuropsychiatric events associated with
leukotriene-modifying agents: A systematic review. Drug Saf.
41:253–265. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marques CF, Marques MM and Justino GC:
Leukotrienes vs. Montelukast-Activity, Metabolism, and Toxicity
Hints for Repurposing. Pharmaceuticals (Basel). 15:10392022.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zovko A, Yektaei-Karin E, Salamon D,
Nilsson A, Wallvik J and Stenke L: Montelukast, a cysteinyl
leukotriene receptor antagonist, inhibits the growth of chronic
myeloid leukemia cells through apoptosis. Oncol Rep. 40:902–908.
2018.PubMed/NCBI
|
|
31
|
Burke L, Butler CT, Murphy A, Moran B,
Gallagher WM, O'Sullivan J and Kennedy BN: Evaluation of cysteinyl
leukotriene signaling as a therapeutic target for colorectal
cancer. Front Cell Dev Biol. 4:1032016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sharpe JC, Arnoult D and Youle RJ: Control
of mitochondrial permeability by Bcl-2 family members. Biochim
Biophys Acta. 1644:107–113. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Savari S, Liu M, Zhang Y, Sime W and
Sjolander A: CysLT(1)R antagonists inhibit tumor growth in a
xenograft model of colon cancer. PLoS One. 8:e734662013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Konopleva M, Zhao S, Xie Z, Segall H,
Younes A, Claxton DF, Estrov Z, Kornblau SM and Andreeff M:
Apoptosis. Molecules and mechanisms. Adv Exp Med Biol. 457:217–236.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li X, He S and Ma B: Autophagy and
autophagy-related proteins in cancer. Mol Cancer. 19:122020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Elrashidy RA and Hasan RA: Modulation of
autophagy and transient receptor potential vanilloid 4 channels by
montelukast in a rat model of hemorrhagic cystitis. Life Sci.
278:1195072021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koller A, Bruckner D, Aigner L, Reitsamer
H and Trost A: Cysteinyl leukotriene receptor 1 modulates
autophagic activity in retinal pigment epithelial cells. Sci Rep.
10:176592020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu H, Tian M, Ding C and Yu S: The C/EBP
Homologous Protein (CHOP) transcription factor functions in
endoplasmic reticulum stress-induced apoptosis and microbial
infection. Front Immunol. 9:30832018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rozpedek W, Pytel D, Mucha B, Leszczynska
H, Diehl JA and Majsterek I: The Role of the PERK/eIF2α/ATF4/CHOP
signaling pathway in tumor progression during endoplasmic reticulum
stress. Curr Mol Med. 16:533–544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brush MH, Weiser DC and Shenolikar S:
Growth arrest and DNA damage-inducible protein GADD34 targets
protein phosphatase 1 alpha to the endoplasmic reticulum and
promotes dephosphorylation of the alpha subunit of eukaryotic
translation initiation factor 2. Mol Cell Biol. 23:1292–1303. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Iurlaro R and Munoz-Pinedo C: Cell death
induced by endoplasmic reticulum stress. FEBS J. 283:2640–2652.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hsu HY, Lin TY, Hu CH, Shu DTF and Lu MK:
Fucoidan upregulates TLR4/CHOP-mediated caspase-3 and PARP
activation to enhance cisplatin-induced cytotoxicity in human lung
cancer cells. Cancer Lett. 432:112–120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zheng YZ, Cao ZG, Hu X and Shao ZM: The
endoplasmic reticulum stress markers GRP78 and CHOP predict
disease-free survival and responsiveness to chemotherapy in breast
cancer. Breast Cancer Res Treat. 145:349–358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wolf C, Smith S and van Wijk SJL:
Zafirlukast Induces VHL- and HIF-2alpha-dependent oxidative cell
death in 786-O clear cell renal carcinoma cells. Int J Mol Sci.
23:35672022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Abdel-Raheem IT and Khedr NF:
Renoprotective effects of montelukast, a cysteinyl leukotriene
receptor antagonist, against methotrexate-induced kidney damage in
rats. Naunyn Schmiedebergs Arch Pharmacol. 387:341–353. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pu S, Liu Q, Li Y, Li R, Wu T, Zhang Z,
Huang C, Yang X and He J: Montelukast prevents mice against
acetaminophen-induced liver injury. Front Pharmacol. 10:10702019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fei Z, Zhang L, Wang L, Jiang H and Peng
A: Montelukast ameliorated pemetrexed-induced cytotoxicity in
hepatocytes by mitigating endoplasmic reticulum (ER) stress and
nucleotide oligomerization domain-like receptor protein 3 (NLRP3)
activation. Bioengineered. 13:7894–7903. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fleifel AM, Soubh AA, Abdallah DM, Ahmed
KA and El-Abhar HS: Preferential effect of Montelukast on
Dapagliflozin: Modulation of IRS-1/AKT/GLUT4 and ER stress response
elements improves insulin sensitivity in soleus muscle of a type-2
diabetic rat model. Life Sci. 307:1208652022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheng H, Leff JA, Amin R, Gertz BJ, De
Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D and Somers G:
Pharmacokinetics, bioavailability, and safety of montelukast sodium
(MK-0476) in healthy males and females. Pharm Res. 13:445–448.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dekhuijzen PN and Koopmans PP:
Pharmacokinetic profile of zafirlukast. Clin Pharmacokinet.
41:105–114. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Woodring RN, Gurysh EG, Bachelder EM and
Ainslie KM: Drug delivery systems for localized cancer combination
therapy. ACS Appl Bio Mater. 6:934–950. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pandey M, Wen PX, Ning GM, Xing GJ, Wei
LM, Kumar D, Mayuren J, Candasamy M, Gorain B, Jain N, et al:
Intraductal delivery of nanocarriers for ductal carcinoma in situ
treatment: A strategy to enhance localized delivery. Nanomedicine
(Lond). 17:1871–1889. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Du C, Zhang Q, Wang L, Wang M, Li J and
Zhao Q: Effect of montelukast sodium and graphene oxide
nanomaterials on mouse asthma model. J Nanosci Nanotechnol.
21:1161–1168. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Accolate (zafirlukast). AstraZeneca
Pharmaceuticals LP; Wilmington, DE: 2009
|
|
55
|
Huang CK and Handel N: Effects of
Singulair (montelukast) treatment for capsular contracture. Aesthet
Surg J. 30:404–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Scuderi N, Mazzocchi M, Fioramonti P and
Bistoni G: The effects of zafirlukast on capsular contracture:
Preliminary report. Aesthetic Plast Surg. 30:513–520. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Saier L, Ribeiro J, Daunizeau T, Houssin
A, Ichim G, Barette C, Bouazza L and Peyruchaud O: Blockade of
Platelet CysLT1R receptor with zafirlukast counteracts platelet
protumoral action and prevents breast cancer metastasis to bone and
lung. Int J Mol Sci. 23:122212022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
El-Ashmawy NE, Khedr EG, Khedr NF and
El-Adawy SA: Suppression of epithelial-mesenchymal transition and
SIRT1/AKT signaling pathway in breast cancer by montelukast. Int
Immunopharmacol. 119:1101482023. View Article : Google Scholar : PubMed/NCBI
|
